Trombocitopenia inmune

Abstract

Immune thrombocytopenia is a clinical condition characterized by peripheral destruction of platelets associated with a blood count below 100,000 per cubic millimeter. Mild hemorrhagic manifestations such as petechiae, ecchymosis, and gingivorrhage are the most frequent clinical presentation; however, cases of major bleeding are related to the occurrence of life-threatening complications. Glucocorticoids are used as the first-line treatment of choice. In those patients in whom an appropriate therapeutic response is not achieved, the use of a second-line management alternative such as thrombopoietin receptor agonists and rituximab present acceptable medical evidence results. Splenectomy is not recommended within the first year after the diagnosis of immune thrombocytopenia, except in those cases in which there are no other first-line treatment alternatives.